In a lift for Amgen, the U.S. Supreme Court docket on Friday agreed to listen to a case through which the corporate argued a federal appeals court docket incorrectly decided its patent claims on a ldl cholesterol medicine are invalid.
At concern is a long-running battle between Amgen and a pair of rivals — Sanofi and Regeneron Prescription drugs — over the marketplace for injectable ldl cholesterol therapies. Amgen filed a lawsuit in opposition to the opposite corporations in 2014 for allegedly infringing patents after they sought regulatory approval for their very own medicine. Each medication received U.S. regulatory approval the next 12 months.
Proceed to STAT+ to learn the total story…
